These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 7775113

  • 1. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
    Ghiasi H, Bahri S, Nesburn AB, Wechsler SL.
    Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1352-60. PubMed ID: 7775113
    [Abstract] [Full Text] [Related]

  • 2. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease.
    Ghiasi H, Cai S, Slanina SM, Perng GC, Nesburn AB, Wechsler SL.
    J Infect Dis; 1999 May; 179(5):1086-93. PubMed ID: 10191208
    [Abstract] [Full Text] [Related]

  • 3. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
    Ritchie MH, Oakes JE, Lausch RN.
    Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2460-8. PubMed ID: 8392037
    [Abstract] [Full Text] [Related]

  • 4. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I, Nesburn AB, Yoon S, Zhang X, Mohebbi A, Sue V, Vanderberg A, Wechsler SL, BenMohamed L.
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits.
    Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL.
    Virology; 1998 Dec 05; 252(1):200-9. PubMed ID: 9875329
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein.
    Ghiasi H, Nesburn AB, Wechsler SL.
    Vaccine; 1996 Feb 05; 14(2):107-12. PubMed ID: 8852405
    [Abstract] [Full Text] [Related]

  • 7. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.
    Ghiasi H, Kaiwar R, Nesburn AB, Slanina S, Wechsler SL.
    J Virol; 1994 Apr 05; 68(4):2118-26. PubMed ID: 8138996
    [Abstract] [Full Text] [Related]

  • 8. Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations.
    Ghiasi H, Cai S, Slanina S, Nesburn AB, Wechsler SL.
    Invest Ophthalmol Vis Sci; 1997 May 05; 38(6):1213-21. PubMed ID: 9152241
    [Abstract] [Full Text] [Related]

  • 9. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection.
    Nesburn AB, Ghiasi H, Wechsler SL.
    Invest Ophthalmol Vis Sci; 1990 Aug 05; 31(8):1497-502. PubMed ID: 2167298
    [Abstract] [Full Text] [Related]

  • 10. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.
    Hu K, He X, Yu F, Yuan X, Hu W, Liu C, Zhao F, Dou J.
    Immunol Invest; 2011 Aug 05; 40(3):265-78. PubMed ID: 21204603
    [Abstract] [Full Text] [Related]

  • 11. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
    Inoue T, Inoue Y, Nakamura T, Yoshida A, Takahashi K, Inoue Y, Shimomura Y, Tano Y, Fujisawa Y, Aono A, Hayashi K.
    Invest Ophthalmol Vis Sci; 2000 Dec 05; 41(13):4209-15. PubMed ID: 11095617
    [Abstract] [Full Text] [Related]

  • 12. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ, Morrison LA, Knipe DM.
    Virology; 2001 Sep 30; 288(2):256-63. PubMed ID: 11601897
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA, Knipe DM.
    Virology; 1997 Dec 22; 239(2):315-26. PubMed ID: 9434723
    [Abstract] [Full Text] [Related]

  • 15. Corneal macrophage infiltrates following ocular herpes simplex virus type 1 challenge vary in BALB/c mice vaccinated with different vaccines.
    Ghiasi H, Hofman FM, Wallner K, Cai S, Perng G, Nesburn AB, Wechsler SL.
    Vaccine; 2000 Dec 08; 19(9-10):1266-73. PubMed ID: 11137266
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines.
    Osorio Y, Cohen J, Ghiasi H.
    Invest Ophthalmol Vis Sci; 2004 Feb 08; 45(2):506-14. PubMed ID: 14744892
    [Abstract] [Full Text] [Related]

  • 18. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ, Gurung HR, Jinkins JK, Geltz JJ, Wu JL, Halford WP, Carr DJJ.
    J Virol; 2016 Jun 01; 90(11):5514-5529. PubMed ID: 27030264
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.